Patients with ulcerative colitis have a higher risk for cancer than the general population, with variations in cancer incidence more pronounced with age than with treatment status.

Objective To evaluate golimumab's effect on MRI-detected spinal inflammation in ankylosing spondylitis (AS). Methods Patients were randomly assigned to subcutaneous injections of placebo (n=78), ...

1 Other SC-injected bDMARDs subsequently approved to treat rheumatic diseases include adalimumab and certolizumab pegol. Golimumab was approved in 2009 as an SC injection to treat moderately to ...

Methods Adults with active PsA (≥3 swollen and tender joints, active psoriasis) were randomly assigned to subcutaneous placebo, golimumab 50 mg, or golimumab 100 mg every 4 weeks (q4wks) through wk20.